Dunne J W, Heye N, Dunne S L
Neurophysiology Laboratory, Royal Perth Hospital, Australia.
J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):232-5. doi: 10.1136/jnnp.58.2.232.
The purpose of this open study was to find out whether botulinum toxin A (BTX-A) relieves the signs and symptoms of chronic limb spasticity. The study comprised 40 patients, aged 12-82 years, with moderate to severe spasticity of the upper (13) or lower limbs (27) refractory to conventional physical and medical treatments. Outcome measures were clinical and blinded videotape assessments of spasticity and motor function. Electromyography guided BTX-A injections were given in one or two sessions at total doses averaging 175 U in the upper limb (range 70-270 U) and 221 U in the lower limb (range 100-500 U). Thirty four patients (85%) derived worthwhile benefit, with improved limb posture and increased range of passive motion in 31, pain reduction in 28 of 31 with pain, and improved function in 16. Side effects were limited to local and usually mild discomfort from the injections (19), symptomatic local weakness (one), and local infection (one). Preliminary experience indicates that BTX-A is a promising adjunctive treatment for selected patients with spasticity.
这项开放性研究的目的是确定A型肉毒毒素(BTX-A)是否能缓解慢性肢体痉挛的体征和症状。该研究纳入了40例年龄在12至82岁之间的患者,这些患者的上肢(13例)或下肢(27例)存在中度至重度痉挛,对传统物理和药物治疗无效。疗效指标包括对痉挛和运动功能的临床及盲法录像评估。在肌电图引导下进行BTX-A注射,分一至两个疗程,上肢平均总剂量为175单位(范围70 - 270单位),下肢为221单位(范围100 - 500单位)。34例患者(85%)获得了显著益处,31例患者的肢体姿势改善、被动活动范围增加,31例有疼痛的患者中有28例疼痛减轻,16例患者功能改善。副作用仅限于注射部位局部且通常为轻度不适(19例)、症状性局部无力(1例)和局部感染(1例)。初步经验表明,BTX-A对选定的痉挛患者是一种有前景的辅助治疗方法。